The first patients in each of two early-stage clinical trials testing CRISPR-based treatments for inherited blood disorders have been symptom free for several months with normalized hemoglobin levels, the companies developing the therapies announced today (November 19). Both participants experienced only treatable, temporary side effects, according to the data.
Last fall, Switzerland-headquartered CRISPR Therapeutics and Vertex Pharmaceuticals in Boston teamed up to launch a trial in Germany testing a CRISPR-based approach to treating -thalassemia. The therapy, known as CTX001, is applied to blood stem cells removed from the patient to cleave the BCL11A gene that represses the production of fetal hemoglobin. These cells are then reinfused to provide a healthy supply this protein, normally only produced in infancy, to overcome problems associated with mutations in the gene encoding the adult version. A few months later, the two companies launched a parallel trial in Nashville, Tennessee, to test CTX001 in sickle cell patients, who also suffer from mutations in the gene for adult hemoglobin.
The data released this week pertains to the first patients treated, one in each of these trials. In both participants, the CRISPRed cells successfully homed to the bone marrow. In the nine months since she received the treatment, the -thalassemia patient has required no blood transfusions, which she had needed regularly for 16 years, and her total hemoglobin levels are near-normal, STATreports. Meanwhile, the sickle-cell patient has not suffered any of the painful and organ-damaging events known as vaso-occlusive crises, where the misshapen blood cells characteristic of the disease stick to and clog small blood vessels, since she received her treatment in July, and her total hemoglobin levels have also normalized, according to STAT.
We are very, very excited, Haydar Frangoul, the treating physician at the Sarah Cannon Research Institute in Nashville, tells NPR. This preliminary data shows for the first time that gene editing has actually helped a patient with sickle cell disease. This is definitely a huge deal.
Both patients experienced only minimal side effects, which the treating physicians attributed to the drug busulfan, used to wipe out the patients mutant bone marrow cells before receiving the infusion of CRISPRed blood stem cells.
These results are remarkable because they represent the first clinical evidence that CRISPR-Cas9 has real curative potential, Jeff Leiden, the president and chief executive officer of Vertex Pharmaceuticals, tells STAT. Vertex and CRISPR Therapeutics say they will now proceed with enrolling a total of 45 patients in each trial.
Jef Akst is managing editor ofThe Scientist. Email her atjakst@the-scientist.com.
View original post here:
Early Results Are Positive for Experimental CRISPR Therapies - The Scientist
- I took an international trip with my frozen eggs to learn about the fertility industry - MIT Technology Review - September 16th, 2022
- GM begins US Ultium battery production for Hummer EV in Ohio amidst union pushback - Electrek.co - September 8th, 2022
- On the scent: ETSU researchers exploring treatments for loss of smell - East Tennessee State University - September 8th, 2022
- University of Minnesota researcher seeks to sustain Alzheimer's findings amid image scandal - Star Tribune - August 5th, 2022
- Men Share The Costly Lengths They've Taken To Prevent Balding - HuffPost - July 11th, 2022
- The end of Roe v. Wade affects more than just abortion - Vox.com - July 3rd, 2022
- What Is Radiation Sickness and Are There Drugs to Treat It? - Newsweek - May 15th, 2022
- IMAC Holdings, Inc. Announces Initiation of Third and Final Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for... - March 25th, 2022
- Roslin Tech in multi-million bid to fund sustainable food - HeraldScotland - August 31st, 2021
- What Is DiscGenics, The Company Christopher Duntsch Helped Found, And Where Is It Today? - Oxygen - July 21st, 2021
- Karen Hasty Named Among 2021 Super Women In Business by Memphis Business Journal - UTHSC News - June 6th, 2021
- GM pledges to be carbon neutral by 2040; Dingell applauds efforts - Dearborn Press and Guide - February 16th, 2021
- Former NFL star Eddie George returns to Vero Beach for therapy, this time on shoulder - TCPalm - September 22nd, 2020
- US Performing Hysterectomies On Immigrants? - The Shadow League - September 22nd, 2020
- Sunway University's Collaboration with Harvard Medical School Makes Advances in Potential Cancer Treatment using Gene Therapy - Yahoo Finance - August 26th, 2020
- Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network - March 28th, 2020
- CAR T Cells to Go? Outpatient Therapy Can Be Safe - Medscape - March 1st, 2020
- Breakthrough, Non-Invasive Treatment Called Axol Therapy For Erectile Dysfunction And Enhanced Sexual Performance Now Available At Colorado Urology -... - March 1st, 2020
- Alberta baby Mighty Hudson home after gene therapy: hes cured - Global News - January 24th, 2020
- Year in Review: The Top Science Stories of 2019 - WTTW News - January 5th, 2020
- Towards a universal flu vaccine - Scientific American - September 23rd, 2019
- What We Do Stem Cell Institute of Middle Tennessee - March 20th, 2019
- UTHSC | Department of Ophthalmology | Hamilton Eye Institute - March 7th, 2019
- Stem Cell Treatment Nashville TN - Precision Pain Care - January 15th, 2019
- Equine Regenerative Medicine - University of Tennessee system - September 15th, 2018
- Lung Institute | Stem Cell Treatment Tennessee - September 25th, 2017
- EPS for BioLife Solutions (BLFS) Expected At $-0.06; Last Week Dean Foods Co (DF) Coverage - Herald KS - July 30th, 2017
- Stem Cell Therapy Franklin TN | Stem Cell Treatment - July 7th, 2017
- When C9ORF72 Silences U2, Spliceosomes Can't Find What They're Looking For - Alzforum - July 7th, 2017
- Knoxville TN Stem Cell Treatment | Knoxville Tennessee ... - November 23rd, 2016
- Lung Institute | Stem Cell Treatment Center in TN for Lung ... - November 9th, 2016
- The Stem Cell Transplant Process - Covenant Health - May 12th, 2015
- SpringerPlus | Full text | What makes cancer stem cell ... - April 27th, 2015
- Pros And Cons Of Stem Cell Research - Popular Issues ... - January 29th, 2015
- Chattanoogan.com - Chattanooga's source for breaking local news - November 26th, 2014
- Stem Cell Transplants in Dogs | eHow - eHow | How to ... - November 19th, 2014
- Memphis Tennessee Stem Cell Research | Memphis TN Stem ... - November 11th, 2014
- Human stem cell research - Religious Tolerance - September 27th, 2014
- Stem Cells Macular DegenerationStem Cell Treatments - September 27th, 2014
- Understanding Stem Cell Transplant VICC Momentum - September 27th, 2014
- Tennessee in middle of embryonic stem cell fight | wbir.com - August 26th, 2014
- Stem Cell Transplant Program - Covenant Health - August 23rd, 2014
- Tennessee Stem Cell Therapy | Stem Cell Treatments - August 22nd, 2014